Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven ...
Tiny RNA fragments can predict two-year survival better than traditional health metrics. Researchers from Duke Health and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results